人肝癌细胞HepG2

细胞名称

人肝癌细胞HepG2                  

货物编码

BFN60800692

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研用途               1类

培养体系

DMEM高糖培养基（Hyclone）+10%胎牛血清（Gibco）+1%双抗（Hyclone）

培养温度

37℃

二氧化碳浓度

5%

简介

人肝癌细胞HepG2细胞来源于一名15岁的白人少年的肝癌组织。该细胞表达甲胎蛋白、白蛋白、α-2-巨球蛋白、α-1-抗胰蛋白酶、转铁蛋白、α-1-抗凝乳蛋白酶、结合珠蛋白、铜蓝蛋白、纤溶酶原、补体C4、C3激活物、纤维蛋白原、α-1酸性糖蛋白、α-2-HS-糖蛋白、β-脂蛋白、视黄醇结合蛋白；表达胰岛素受体和胰岛素样生长因子IGFⅡ的受体；该细胞具有3-羟基-3-甲酰辅酶A还原酶和肝甘油三酯脂肪酶的活性。目前尚未证明该细胞中有HBV基因组。 人肝癌细胞HepG2细胞由青旗（上海）生物技术发展有限公司于2019年引种自ATCC（HB-8065)。

注释

Problematic cell line: Misidentified. Originally thought to be a hepatocellular carcinoma cell line but shown to be from an hepatoblastoma (PubMed=19751877).

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: ENCODE project common cell types; tier 1.

Part of: JFCR45 cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: TCGA-110-CL cell line panel.

Doubling time: ~50-60 hours (DSMZ).

Omics: Deep antibody staining analysis.

Omics: Deep exome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Genome sequenced.

Omics: H3K27ac ChIP-seq epigenome analysis.

Omics: H3K27me3 ChIP-seq epigenome analysis.

Omics: H3K36me3 ChIP-seq epigenome analysis.

Omics: H3K4me1 ChIP-seq epigenome analysis.

Omics: H3K4me2 ChIP-seq epigenome analysis.

Omics: H3K4me3 ChIP-seq epigenome analysis.

Omics: H3K79me2 ChIP-seq epigenome analysis.

Omics: H3K9ac ChIP-seq epigenome analysis.

Omics: H3K9me3 ChIP-seq epigenome analysis.

Omics: H4K20me1 ChIP-seq epigenome analysis.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: Secretome proteome analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Omics: Virome analysis using proteomics.

STR信息

Amelogenin：X，Y；CSF1PO：10，11；D13S317：9，13；D16S539：12，13；D18S51：13，14；D19S433：15.2；D21S11：29，31；D2S1338：19，20；D3S1358：15，16；D5S818：11，12；D7S820：10；D8S1179：15，16；FGA：22，25；TH01：9；TPOX：8，9；vWA：17；

参考文献

PubMed=233137; DOI=10.1038/282615a0

Aden D.P., Fogel A., Plotkin S.A., Damjanov I., Knowles B.B.

Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line.

Nature 282:615-616(1979)

PubMed=6248960; DOI=10.1126/science.6248960

Knowles B.B., Howe C.C., Aden D.P.

Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.

Science 209:497-499(1980)

Patent=US4393133

Knowles B.B., Aden D.P.

Human hepatoma derived cell line, process for preparation thereof, and uses therefor.

Patent number US4393133, 12-Jul-1983

PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x

Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.J., Revillard J.-P.

Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.

Eur. J. Biochem. 165:699-704(1987)

PubMed=8384076; DOI=10.1016/0165-4608(93)90227-D

Chen H.-L., Chiu T.-S., Chen P.-J., Chen D.-S.

Cytogenetic studies on human liver cancer cell lines.

Cancer Genet. Cytogenet. 65:161-166(1993)

PubMed=8389256; DOI=10.1093/carcin/14.5.987

Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.

p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.

Carcinogenesis 14:987-992(1993)

PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x

Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.

HLA expression in hepatocellular carcinoma cell lines.

Clin. Exp. Immunol. 97:328-333(1994)

DOI=10.11418/jtca1981.16.3_173

Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ohashi R., Namba M.

The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.

Tissue Cult. Res. Commun. 16:173-178(1997)

PubMed=9178645; DOI=10.1006/cimm.1997.1108

Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.

CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.

Cell. Immunol. 177:176-181(1997)

PubMed=9359923; DOI=10.18926/AMO/30789

Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ishioka C., Namba M.

Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.

Acta Med. Okayama 51:261-265(1997)

PubMed=11050057; DOI=10.1053ep.2000.19349

Wong N., Lai P., Pang E., Leung T.W.-T., Lau J.W.-L., Johnson P.J.

A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping.

Hepatology 32:1060-1068(2000)

PubMed=12029633; DOI=10.1053ep.2002.33683

Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.

TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Hepatology 35:1476-1484(2002)

PubMed=12068308; DOI=10.1038/nature00766

Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)

DOI=10.1385/CP:1:3-4:313

Pang R.T.K., Poon T.C.W., Wong N., Lai P.B.-S., Wong N.L.Y., Chan C.M.L., Yu J.W.S., Chan A.T.C., Sung J.J.Y.

Comparison of protein expression patterns between hepatocellular carcinoma cell lines and a hepatoblastoma cell line.

Clin. Proteomics 1:313-331(2004)

PubMed=14980111

Zhai B.-J., Wu F., Shao Z.-Y., Hu K., Zhao C.L., Wang Z.-B.

Establishment of human hepatocellular carcinoma multidrug-resistance cell line (HepG2/Adm) and study apoptosis induced by low-frequency pulse ultrasound exposure.

Zhonghua Gan Zang Bing Za Zhi 12:95-98(2004)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234

Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.

Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

Mol. Cancer Ther. 4:399-412(2005)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001

Azari S., Ahmadi N., Tehrani M.J., Shokri F.

Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.

Biologicals 35:195-202(2007)

PubMed=19751877; DOI=10.1016/j.humpath.2009.07.003

Lopez-Terrada D.H., Cheung S.W., Finegold M.J., Knowles B.B.

Hep G2 is a hepatoblastoma-derived cell line.

Hum. Pathol. 40:1512-1515(2009)

PubMed=20069059; DOI=10.1155/2010/437143

Srisomsap C., Sawangareetrakul P., Subhasitanont P., Chokchaichamnankit D., Chiablaem K., Bhudhisawasdi V., Wongkham S., Svasti J.

Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes.

J. Biomed. Biotechnol. 2010:437143-437143(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20228232; DOI=10.1124/dmd.109.031831

Hart S.N., Li Y., Nakamoto K., Subileau E.-A., Steen D., Zhong X.-B.

A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

Drug Metab. Dispos. 38:988-994(2010)

PubMed=21269460; DOI=10.1186/1752-0509-5-17

Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.

Initial characterization of the human central proteome.

BMC Syst. Biol. 5:17-17(2011)

PubMed=22278370; DOI=10.1074/mcp.M111.014050

Geiger T., Wehner A., Schaab C., Cox J., Mann M.

Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.

Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=22460905; DOI=10.1038/nature11003

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=23325432; DOI=10.1101/gr.147942.112

Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.

Dynamic DNA methylation across diverse human cell lines and tissues.

Genome Res. 23:555-567(2013)

PubMed=23505090; DOI=10.1002/hep.26402

Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.

Hepatology 58:706-717(2013)

PubMed=23887712; DOI=10.1038/ncomms3218

Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Nat. Commun. 4:2218-2218(2013)

PubMed=24116068; DOI=10.1371/journal.pone.0075692

Weiskirchen R., Weimer J., Meurer S.K., Kron A., Seipel B., Vater I., Arnold N., Siebert R., Xu L.-M., Friedman S.L., Bergmann C.

Genetic characteristics of the human hepatic stellate cell line LX-2.

PLoS ONE 8:E75692-E75692(2013)

PubMed=24618588; DOI=10.1371/journal.pone.0091433

Chernobrovkin A.L., Zubarev R.A.

Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.

PLoS ONE 9:E91433-E91433(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:E954893-E954893(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311

Cevik D., Yildiz G., Ozturk M.

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

World J. Gastroenterol. 21:311-317(2015)

PubMed=26160117; DOI=10.1093/toxsciv136

Sison-Young R.L.C., Mitsa D., Jenkins R.E., Mottram D., Alexandre E., Richert L., Aerts H., Weaver R.J., Jones R.P., Johann E., Hewitt P.G., Ingelman-Sundberg M., Goldring C.E.P., Kitteringham N.R., Park B.K.

Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication.

Toxicol. Sci. 147:412-424(2015)

PubMed=26825538; DOI=10.1016/j.jprot.2016.01.016

Wisniewski J.R., Vildhede A., Noren A., Artursson P.

In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes.

J. Proteomics 136:234-247(2016)

PubMed=27329724; DOI=10.18632/oncotarget.10161

Watari K., Nishitani A., Shibata T., Noda M., Kawahara A., Akiba J., Murakami Y., Yano H., Kuwano M., Ono M.

Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.

Oncotarget 7:47403-47417(2016)

PubMed=27470094; DOI=10.1016/j.chroma.2016.07.042

Liu Z.-Y., Wang F.-J., Chen J., Zhou Y., Zou H.-F.

Modulating the selectivity of affinity absorbents to multi-phosphopeptides by a competitive substitution strategy.

J. Chromatogr. A 1461:35-41(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

DOI=10.1101/378497

Zhou B., Ho S.S., Greer S.U., Spies N., Bell J.M., Zhang X., Zhu X., Arthur J.G., Byeon S., Pattni R., Saha I., Song G., Ji H.P., Perrin D., Wong W.H., Abyzov A., Urban A.E.

Haplotype-resolved and integrated genome analysis of ENCODE cell line HepG2.

bioRxiv 2018:378497-378497(2018)

PubMed=29610054; DOI=10.1016/j.dmpk.2018.03.003

Shi J., Wang X., Lyu L., Jiang H., Zhu H.-J.

Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes.

Drug Metab. Pharmacokinet. 33:133-140(2018)

PubMed=29660373; DOI=10.1016/j.bbagen.2018.04.012

Touat-Hamici Z., Bulteau A.-L., Bianga J., Jean-Jacques H., Szpunar J., Lobinski R., Chavatte L.

Selenium-regulated hierarchy of human selenoproteome in cancerous and immortalized cells lines.

Biochim. Biophys. Acta 1862:2493-2505(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2

Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

Nat. Commun. 10:3574-3574(2019)